Clinical trial
A Post Marketing Surveillance on Piqray (Alpelisib) in Korea
NCT05293470 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Post Marketing Surveillance on Piqray (Alpelisib) in Korea
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- June 29, 2022
- Completion date
- May 12, 2027
- Enrollment
- 900 (estimated)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer